CD8A and neoplasm: First, we depleted T cells by administering anti-CD4 and anti-CD8 antibodies, delivered every 4 days starting 2 days before tumor inoculation, using 500μjg for the first dose and 250μjg for the subsequent doses, in mice orthotopically injected with PyMT cells and concomitantly receiving IgG or mDKN01.